@abfero.com
Our mission is to develop best-in-class, safe and effective oral iron chelators for the treatment of diseases of iron overload.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Abfero Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing safe and effective oral iron chelators for the treatment of diseases caused by iron overload. The company's mission is to address the risks of severe organ damage and death faced by patients with systemic iron overload due to transfusions or genetic conditions. Additionally, Abfero focuses on combating iron accumulation in the retina and brain, which is associated with debilitating conditions such as vision loss and neurodegeneration.
Abfero's lead candidate, SP-420, is a brain-penetrant small molecule that holds great potential as an addition to existing chelating therapies. The company's small molecule technology and clinical-stage pipeline aim to provide urgently needed treatment options for both systemic iron overload and local iron overload, which affect a growing population of aging patients. With a focus on treating age-related macular degeneration, the leading cause of irreversible blindness in the United States, Abfero aims to develop innovative approaches to retinal degeneration by removing iron from the retina.
Furthermore, their highly tolerable small molecule technology and novel dosing regimen show promise in addressing transfusional iron overload. Abfero Pharmaceuticals is committed to advancing their mission of treating diseases caused by iron overload and improving patients' lives
Company Type
Privately Held
Company Size
2-10
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories